Global myelodysplastic syndromes market 2020-2027 Market Research Report| Know The Growth Factors and Future Scope

This Global myelodysplastic syndromes market analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken from consistent sources such as websites, annual reports of the companies, and journals which is then checked and validated by the market experts. Global myelodysplastic syndromes market report has been structured with transparent research studies which makes it of supreme quality. By exactly understanding customer requirement, one or more methods are used to construct this finest market research report. The report provides with CAGR value fluctuation during the forecast period of 2020 – 2025 for the market.

Global myelodysplastic syndromes market is rising gradually with a healthy CAGR of 11.09% in the forecast period of 2019-2026. Increasing geriatric population, growing awareness about the diseases and improving healthcare expenditure are some major drivers for the market growth. Global Myelodysplastic Syndromes Market By Type (Myelodysplastic Syndrome with Unilineage Dysplasia, Myelodysplastic Syndrome with Multilineage Dysplasia, Myelodysplastic Syndrome with Ring Sideroblasts, Others), Diagnosis (Complete Blood Count, Bone Marrow Aspiration, Biopsy, Others), Treatment (Medication, Blood Transfusion, Bone Marrow Transplantation, Others), Route of Administration (Oral, Injectable and Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2026

Some of the key players from the complete study are Astex Pharmaceuticals, Otsuka Holdings Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., Lupin, Takeda Pharmaceutical Company Limited, Onconova Therapeutics, Helsinn Healthcare SA, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., MEI Pharma Inc., Aprea Therapeutics, Boston Biomedical, AbbVie Inc., Acceleron Pharma, Inc., BerGenBio ASA, CELGENE CORPORATION, Eisai Co., Ltd. among others.

Get Sample Report + All Related Graphs & Charts @

Market Definition: 

Myelodysplastic syndromes are a rare group of hematological diseases that are caused by formation of abnormal blood-forming cells in the bone marrow. It occurs due to the mutation of one or more genes which controls the development of blood cells. These are also referred as bone marrow failure disorder. In myelodysplastic syndrome the bone marrow fails to produce healthy red blood cells, white blood cells and or platelets. The most common symptoms of myelodysplastic syndromes are fatigue, weakness, shortness of breath, bone pain and others. The symptoms and severity of MDS varies from person to person.

The prevalence of MSD is estimated to be approximately 22 to 45 cases per 100,000 people over the age of 70. This disease occurs slightly more in males than females. MSD can develop in any age group but it mostly affects population over the age of 60 years.

Market Drivers

Increasing geriatric population which has a tendency of getting effected with myelodysplastic syndrome acts as a market driver
Technological advancements in the sequencing technologies also drives this market growth
Government initiatives for research and development of target specific therapies and  favorable reimbursement policies will also boost this market growth in the forecast period
Growing awareness about the diseases associated with MDS is expected to drive the market growth

Market Restraints

High cost therapies of myelodysplastic syndromes restricts the market growth
Novel treatment options due to the complexity and heterogeneity of  can hamper the market growth

Order a Copy of This Research Report @


By Type

Myelodysplastic Syndrome with Unilineage Dysplasia
Myelodysplastic Syndrome with Multilineage Dysplasia
Myelodysplastic Syndrome with Ring Sideroblasts

By Diagnosis

Complete Blood Count
Bone Marrow Aspiration and Biopsy

By Treatment

Blood Transfusion
Bone Marrow Transplantation

By Route of Administration


By End Users

Specialty Clinics

By Distribution Channels

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Key Developments in the Market:

In September 2019, Astex Pharmaceuticals received the Orphan Drug designation for the U. S. FDA for ASTX727, a novel oral hypomethylating agent used for treatment of patients with Myelodysplastic Syndromes (including chronic myelomonocytic leukemia). Astex Pharmaceuticals is a subsidiary of Otsuka Holdings Co., Ltd. and TAIHO PHARMACEUTICAL CO., LTD. The grant of this designation to the drug will provide a seven year market exclusivity in the United States, to the company
In November 2018, Lupin received marketing approval from the U. S. FDA for Decitabine, the generic version of dacogen for treatment of patients with myelodysplastic syndrome. This productis available in injectable dosage form and has similar efficacy to dacogen with treated and untreated, de novo and secondary MDS. This approval provides the marketing grant of Otsuka Pharmaceutical Co. Ltd.’s dacogen and increase the market size of Lupin

Reasons to Purchase this Report

Current and future of global myelodysplastic syndromes market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
Regions/Countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players

View Detailed TOC @


Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: [email protected]

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Leave a Reply

Your email address will not be published. Required fields are marked *